Myeloid Immune Cells CARrying a New Weapon Against Cancer

Frontiers in Cell and Developmental Biology

Vanderson Rocha¹  José Alexandre M. Barbuto²  Theo Gremen M. Oliveira⁴  Samuel Campanelli Freitas Couto⁴  Tarcio Teodoro Braga⁵  Rodrigo Nalio Ramos⁶  Eduardo Magalhães Rego⁶  Paulo Klinger⁷ 

[1] Churchill Hospital, Department of Hematology, University of Oxford, Oxford, United Kingdom;Departamento de Imunologia, Instituto de CienciasBiomedicas, Universidade de Sao Paulo, São Paulo, Brazil;Department of Pathology, Federal University of Parana, Curitiba, Brazil;Fundação Pró-Sangue–Hemocentro de São Paulo, São Paulo, Brazil;Graduate Program in Biosciences and Biotechnology, Instituto Carlos Chagas, Fiocruz-Parana, Curitiba, Brazil;Instituto D’Or de Ensino e Pesquisa, São Paulo, Brazil;Laboratory of Medical Investigation in Pathogenesis and Directed Therapy in Onco-Immuno-Hematology (LIM-31), Departament of Hematology and Cell Therapy, Hospital das Clínicas HCFMUSP, Faculdade de Medicina, University of São Paulo, São Paulo, Brazil;

关键词: CAR (chimeric antigen receptor);    monocyte;    myeloid cells;    solid tumor (malignancy and long term complications);    macrophages;    dendritic cell (DC);   

DOI  :  10.3389/fcell.2021.784421

来源: DOAJ

【 摘 要 】

Chimeric antigen receptor (CAR) engineering for T cells and natural killer cells (NK) are now under clinical evaluation for the treatment of hematologic cancers. Although encouraging clinical results have been reported for hematologic diseases, pre-clinical studies in solid tumors have failed to prove the same effectiveness. Thus, there is a growing interest of the scientific community to find other immune cell candidate to express CAR for the treatment of solid tumors and other diseases. Mononuclear phagocytes may be the most adapted group of cells with potential to overcome the dense barrier imposed by solid tumors. In addition, intrinsic features of these cells, such as migration, phagocytic capability, release of soluble factors and adaptive immunity activation, could be further explored along with gene therapy approaches. Here, we discuss the elements that constitute the tumor microenvironment, the features and advantages of these cell subtypes and the latest studies using CAR-myeloid immune cells in solid tumor models.

【 授权许可】

Unknown